[HTML][HTML] Maraba virus as a potent oncolytic vaccine vector

JG Pol, L Zhang, BW Bridle, KB Stephenson… - Molecular therapy, 2014 - cell.com
JG Pol, L Zhang, BW Bridle, KB Stephenson, J Rességuier, S Hanson, L Chen, N Kazdhan…
Molecular therapy, 2014cell.com
The rhabdovirus Maraba has recently been characterized as a potent oncolytic virus. In the
present study, we engineered an attenuated Maraba strain, defined as MG1, to express a
melanoma-associated tumor antigen. Its ability to mount an antitumor immunity was
evaluated in tumor-free and melanoma tumor-bearing mice. Alone, the MG1 vaccine
appeared insufficient to prime detectable adaptive immunity against the tumor antigen.
However, when used as a boosting vector in a heterologous prime-boost regimen, MG1 …
The rhabdovirus Maraba has recently been characterized as a potent oncolytic virus. In the present study, we engineered an attenuated Maraba strain, defined as MG1, to express a melanoma-associated tumor antigen. Its ability to mount an antitumor immunity was evaluated in tumor-free and melanoma tumor-bearing mice. Alone, the MG1 vaccine appeared insufficient to prime detectable adaptive immunity against the tumor antigen. However, when used as a boosting vector in a heterologous prime-boost regimen, MG1 vaccine rapidly generated strong antigen-specific T-cell immune responses. Once applied for treating syngeneic murine melanoma tumors, our oncolytic prime-boost vaccination protocol involving Maraba MG1 dramatically extended median survival and allowed complete remission in more than 20% of the animals treated. This work describes Maraba virus MG1 as a potent vaccine vector for cancer immunotherapy displaying both oncolytic activity and a remarkable ability to boost adaptive antitumor immunity.
cell.com